


Preclinical evaluation of a novel ATMP as „off-the shelf” CAR product for precision immunotherapy of cancer



PRINCIPLE INVESTIGATOR:
Prof. Dr. Gabriele Pecher
Charité



SUMMARY

Cancer still remains the second leading cause of death worldwide. Tumors often do not respond to standard treatment and become essentially incurable.

The team develops a novel advanced therapy medicinal product (ATMP) for the precision immunotherapy of both solid tumors and hematological diseases to generate an allogeneic, “off-the-shelf” CAR-modified therapeutic agent. The preclinical development will be completed and a clinical trial will be prepared.

PROJECT GOALS

- Development of a novel allogeneic ATMP for anti-cancer therapy
- Preclinical development completed
- Preparation of a phase I / II clinical trial

LONG-TERM GOALS

- Perform phase I / II clinical trial
- License to Pharma or Startup foundation